openPR Logo
Press release

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2024-2033: Competitor Assessment, New Trends, Share Analysis And Global Key Players

07-25-2024 04:30 PM CET | Health & Medicine

Press release from: The Business Research Company

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market

"The new report published by The Business Research Company, titled Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the methicillin-resistant staphylococcus aureus (mrsa) drugs market size has grown strongly in recent years. It will grow from $2.26 billion in 2023 to $2.38 billion in 2024 at a compound annual growth rate (CAGR) of 5.2%. The methicillin-resistant staphylococcus aureus (mrsa) drugs market size is expected to see strong growth in the next few years. It will grow to $2.9 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10859&type=smp

Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections
The increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is expected to propel the growth of the methicillin-resistant Staphylococcus aureus drugs market going forward. A methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by Staphylococcus bacteria that is resistant to some antibiotics used for treating ordinary staph infections. MRSA infections must be treated with drugs that destroy and inhibit the growth of MRSA bacteria in humans and animals. For instance, in November 2022, according to the Centers for Disease Control and Prevention, a US-based health agency under the Department of Health and Human Services, hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections increased by 14% from 2020 to 2021. Further, in December 2022, according to a report by Statens Serum Institute, a Denmark-based sector research institute on MRSA - disease prevalence, in 2021, the number of community-acquired infections with recorded contact with a hospital or the nursing sector in the previous six months was 181, up from 159 in 2020. Therefore, the increase in the prevalence of methicillin-resistant Staphylococcus aureus infections is driving the growth of the methicillin-resistant Staphylococcus aureus drug market.

Driving Innovation In The Mrsa Drug Market With Breakthrough Treatment For Acute Bacterial Skin Infection
Product innovation is the key trend gaining popularity in the Methicillin-Resistant Staphylococcus aureus (MRSA) drug market. Major companies involved in the Methicillin-Resistant Staphylococcus Aureus (MRSA) drug market are focused on innovating new products to improve their observation power and sustain their position in the market. For instance, in March 2021, Melinta Therapeutics LLC, a US-based biopharmaceutical firm, announced the FDA approval of Kimyrsa (oritavancin), indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). Kimyra is the first oritavancin one-hour infusion product prepared from one 1,200 mg vial and is compatible with both 0.9% sodium chloride injection (NS) and 5% dextrose in sterile water (D5W). The drug acts by inhibiting transpeptidation, inhibiting transglycosylation, and disrupting cell membrane integrity.

The methicillin-resistant staphylococcus aureus (mrsa) drugs market covered in this report is segmented -

1) By Drug Class: Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, Lipoglycopeptide, Other Drug Classes
2) By Indication: Skin Infections, Bone and Joint Infections, Bacteremia, Animal Infections
3) By MRSA Type: Hospital-Acquired (HA-MRSA), Community-Acquired (CA-MRSA)
4) By Route of Administration: Oral Administration, Parenteral Administration
5) By End User: Hospitals and Clinics, Research and Academic Institutes, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=10859&type=discount

Major companies operating in the methicillin-resistant staphylococcus aureus (mrsa) drugs market report are Basilea Pharmaceutica Ltd., Merck & Co Inc., Pfizer Inc., Theravance Biopharma Inc., Allergan plc, Cumberland Pharmaceuticals Inc., Debiopharm International S.A., The Medicines Company, AbbVie Inc., Innovation Pharmaceuticals Inc., Melinta Therapeutics Inc., Nabriva Therapeutics plc, Paratek Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Absynth Biologics, AmpliPhi Biosciences Corporation, AstraZeneca plc, 3M Co., Meiji Seika Kaisha Ltd., GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Novartis, Wockhardt, Sun Pharmaceutical Industries Ltd., Lupin Limited, Glenmark Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Astellas Pharma Inc.

Contents of the report:
1. Executive Summary
2. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Report Structure
3. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Trends And Strategies
4. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market - Macro Economic Scenario
5. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size And Growth
…..
27. Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2024-2033: Competitor Assessment, New Trends, Share Analysis And Global Key Players here

News-ID: 3598883 • Views:

More Releases from The Business Research Company

Soaring Demand Set to Propel Grant Management Software Market to $4.47 Billion by 2029
Soaring Demand Set to Propel Grant Management Software Market to $4.47 Billion b …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Grant Management Software Market Size Growth Forecast: What to Expect by 2025? The market size of grant management software has escalated quickly in the past few years. The growth is projected to surge from $2.58 billion in 2024 to $2.88 billion by 2025, indicating a compound annual growth rate
Top Market Shifts Transforming the Food Manufacturing Software Market Landscape: Key Insights
Top Market Shifts Transforming the Food Manufacturing Software Market Landscape: …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Food Manufacturing Software Market Size Valuation Forecast: What Will the Market Be Worth by 2025? The market size of food manufacturing software has expanded significantly in the last few years. The worth of the market is projected to increase from $5.35 billion in 2024 to $5.82 billion in 2025,
Granular Permissions Market Expected to Achieve 19% CAGR by 2029: Growth Forecast Insights
Granular Permissions Market Expected to Achieve 19% CAGR by 2029: Growth Forecas …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Granular Permissions Market Through 2025? There has been a significant increase in the size of the granular permissions market in recent years. The market, valued at $2.79 billion in 2024, is expected to reach $3.32 billion in 2025, exhibiting a compound annual
Increasing Number Of Lawsuits Drives The Market Due To Rising Litigation Risks: Transformative Forces Shaping the Excess Liability Insurance Market Landscape in 2025
Increasing Number Of Lawsuits Drives The Market Due To Rising Litigation Risks: …
"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Excess Liability Insurance Market Through 2025? The market for excess liability insurance has shown robust growth in past years, with predictions indicating its increase from $14.78 billion in 2024 to $15.89 billion in 2025, reflecting a compound annual growth rate (CAGR) of

All 5 Releases


More Releases for Staphylococcus

Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections: Po …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Through 2025? In recent times, the market size of drugs for methicillin-resistant staphylococcus aureus (MRSA) has seen continuous growth. The market, which was worth $2.35 billion in 2024, is projected to expand to $2.47 billion in
Leading Growth Driver in the Methicillin-Resistant Staphylococcus Aureus (MRSA) …
What market dynamics are playing a key role in accelerating the growth of the methicillin-resistant staphylococcus aureus (mrsa) drugs market? The growth of the methicillin-resistant Staphylococcus aureus drugs market is expected to be fuelled by the rise in Hospital Acquired Infections (HAIs). Patients acquire these infections while being treated at a healthcare center, usually 48 hours or more post admissions. The root causes behind HAIs include contaminated medical apparatus, lax hand
Staphylococcus Aureus Testing Market In-Depth Market Research Report 2027
A wide range of human clinical infection caused by Staphylococcus Aureus such as Skin, soft tissue, bacteremia, infective endocarditis and others are the major infection caused by Staphylococcus Aureus. The increased use of Staphylococcus Aureus testing in the diagnosis of staph infection grow rapidly, due to the availability of the various advanced test to screen the pathogen efficiently. There is a number of tests present in the market for Staphylococcus
Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018
MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital
Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Maufacturing Cos …
Qyresearchreports include new market research report "Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Size, Status and Forecast 2022" to its huge collection of research reports. The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market is exhibiting steady growth amidst a dynamic business environment. The report is compiled to identify key growth avenues of the global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market and challenges that pose threat to its expansion goals. It also